Form 4: Intellia CMO Sells Shares for Tax Obligations

Intellia Therapeutics' Chief Medical Officer, David Lebwohl, sold 11,903 shares of common stock at $9.21 per share to cover tax withholding obligations related to RSU vesting.

Summary

• David Lebwohl, Executive Vice President and Chief Medical Officer of Intellia Therapeutics, Inc. (NTLA), reported a transaction on January 5, 2026.
• The transaction involved the disposition of 11,903 shares of Intellia Therapeutics Common Stock at a price of $9.21 per share.
• This sale was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) on January 1, 2026.
• The transaction was not a volitional trade by Mr. Lebwohl.
• Following this transaction, Mr. Lebwohl beneficially owns 121,249 shares of common stock.
• The reported beneficial ownership includes 1,022 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025, and 1,264 shares acquired under the same plan on December 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a sale of shares, it's explicitly non-volitional and for tax purposes, not indicative of a lack of confidence. The officer retains a substantial holding.

Positives

• The sale was explicitly stated as a mandatory 'sell-to-cover' for tax purposes, indicating it was not a volitional decision based on a negative outlook for the company.
• The Chief Medical Officer continues to hold a significant number of shares (121,249), demonstrating continued alignment with shareholder interests.

Negatives

• The transaction resulted in a reduction of 11,903 shares from the Chief Medical Officer's direct beneficial ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transaction 'Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.'

Industry Context

This insider transaction report is specific to Intellia Therapeutics and does not provide information directly related to broader industry trends or competitor activities. Such 'sell-to-cover' transactions are common across industries when executive compensation includes Restricted Stock Units.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the non-volitional nature mitigates concerns about management's confidence in the company. The overall impact is negligible.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 details a routine, non-volitional 'sell-to-cover' transaction by a company executive for tax purposes. Such transactions are common and do not typically reflect a change in the executive's outlook on the company's prospects. Therefore, this filing alone does not provide a basis for changing an investment recommendation, and a 'hold' stance is maintained.

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, David Lebwohl, Biotechnology